Pediatric anesthesia & critical care
Levosimendan or Milrinone for Ventricular Septal Defect Repair With Pulmonary Arterial Hypertension
Authors' conclusion
In patients undergoing surgical repair for VSD with PAH, levosimendan does not confer any additional benefit compared to milrinone.
Study context
- Population
- Children 1 month to 12 years with ventricular septal defects (VSD) and pulmonary artery hypertension (PAH) undergoing surgical closure, 2018–2020randomised
- Participants
- 132 children
- Comparison
- Levosimendan vs milrinone
Methodological detailsprospective, single-centre (tertiary-care center)
- Prospective
- Single-centre (tertiary-care center)
Primary result
As reported in the abstract
Low-cardiac-output syndrome / myocardial performance index
- No difference in the myocardial performance index of the left or right ventricle
Further findings
Duration of ventilation · significantly prolonged in the levosimendan group
P = 0.012
Postoperative ICU stay · significantly prolonged in the levosimendan group
P = 0.003
MAP (off CPB, on ICU arrival, 3 and 6 h postop)
- Significantly lower MAP in the levosimendan group
Myocardial performance index (left or right ventricle)
- No difference between groups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Levosimendan or Milrinone for Ventricular Septal Defect Repair With Pulmonary Arterial Hypertension. J Cardiothorac Vasc Anesth. Published 6 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →